

### Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/the-importance-of-diagnosing-dry-eye-disease-early/24201/>

### ReachMD

www.reachmd.com

info@reachmd.com

(866) 423-7849

## The Importance of Diagnosing Dry Eye Disease Early

### ReachMD Announcer:

You're listening to ReachMD. This medical industry feature, titled "The Importance of Diagnosing Dry Eye Disease Early" is sponsored by Bausch + Lomb.

Here's Dr. Marguerite McDonald.

### Dr. McDonald:

My educated guess is that the average patient that sees me has been self-medicating with over-the-counter preparations for about 7 years.

I have a very low threshold before putting them on Rx therapy. Dry eye disease is like every other disease. The earlier you diagnose and treat it, the better the outcomes.

So, if you get someone early in their trajectory, you can make a very immediate difference very quickly.

### Voiceover:

#### Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

#### Important Safety Information

- Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
- In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia, and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritis, and sinusitis.
- To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
- Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.
- Safety and efficacy in pediatric patients below the age of 17 years have not been established.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088

Please see Full Prescribing Information at [Xiidra-ecp.com](http://Xiidra-ecp.com)

### ReachMD Announcer:

This program was sponsored by Bausch + Lomb. If you missed any part of this discussion, visit Industry Features on ReachMD.com, where you can Be Part of the Knowledge.

©2024 Bausch + Lomb. XDR.0262.USA.24